The closing price of BioXcel Therapeutics Inc. (NASDAQ: BTAI) was $19.32 for the day, down -25.49% from the previous closing price of $25.93. In other words, the price has decreased by -$6.61 from its previous closing price. On the day, 3130665 shares were traded. BTAI stock price reached its highest trading level at $26.22 during the session, while it also had its lowest trading level at $17.07.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Our analysis of BTAI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.10 and its Current Ratio is at 6.20. In the meantime, Its Debt-to-Equity ratio is 1.79 whereas as Long-Term Debt/Eq ratio is at 1.79.
Upgrades & Downgrades
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 22 when Mehta Vimal sold 6,500 shares for $25.79 per share. The transaction valued at 167,641 led to the insider holds 37,294 shares of the business.
Steinhart Richard I sold 5,000 shares of BTAI for $135,864 on May 15. The Chief Financial Officer now owns 1,500 shares after completing the transaction at $27.17 per share. On May 15, another insider, Rodriguez Javier, who serves as the See Remarks of the company, sold 1,785 shares for $27.32 each. As a result, the insider received 48,765 and left with 4,350 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BTAI now has a Market Capitalization of 796.89M and an Enterprise Value of 697.32M. For the stock, the TTM Price-to-Sale (P/S) ratio is 987.57 while its Price-to-Book (P/B) ratio in mrq is 10.44. Its current Enterprise Value per Revenue stands at 1.20k whereas that against EBITDA is -3.98.
Stock Price History:
Over the past 52 weeks, BTAI has reached a high of $34.12, while it has fallen to a 52-week low of $8.80. The 50-Day Moving Average of the stock is 21.47, while the 200-Day Moving Average is calculated to be 19.80.
BTAI traded an average of 518.77K shares per day over the past three months and 651.86k shares per day over the past ten days. A total of 28.62M shares are outstanding, with a floating share count of 18.99M. Insiders hold about 31.26% of the company’s shares, while institutions hold 47.90% stake in the company. Shares short for BTAI as of Apr 27, 2023 were 3.54M with a Short Ratio of 3.35M, compared to 3.6M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 12.19% and a Short% of Float of 22.39%.
The firm’s stock currently is rated by 10 analysts. On average, analysts expect EPS of -$1.71 for the current quarter, with a high estimate of -$1.19 and a low estimate of -$1.97, while EPS last year was -$1.35. The consensus estimate for the next quarter is -$1.66, with high estimates of -$1.18 and low estimates of -$1.97.
Analysts are recommending an EPS of between -$5.24 and -$7.95 for the fiscal current year, implying an average EPS of -$6.79. EPS for the following year is -$5.16, with 10 analysts recommending between -$3.93 and -$6.07.
A total of 9 analysts have provided revenue estimates for BTAI’s current fiscal year. The highest revenue estimate was $6.82M, while the lowest revenue estimate was $2.1M, resulting in an average revenue estimate of $4.55M. In the same quarter a year ago, actual revenue was $375k, up 1,113.30% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $37.39M in the next fiscal year. The high estimate is $64M and the low estimate is $9M. The average revenue growth estimate for next year is up 721.80% from the average revenue estimate for this year.